Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE) (NO FEAR-BE)

• ClinicalTrials.gov Identifier: NCT03554356
• Recruitment Status: Recruiting
• First Posted: June 13, 2018
• Last Update Posted: April 11, 2023
• Sponsor: University of North Carolina, Chapel Hill
• Collaborators: PENTAX of America, Inc.; Johns Hopkins University
• Information provided by (Responsible Party): University of North Carolina, Chapel Hill

Study Description

Brief Summary:

A multicenter, prospective, single arm, non randomized clinical trial to evaluate the safety and efficacy of the C2 CryoBalloon Focal Ablation System (CbFAS) for the treatment of persistent dysplasia or intestinal metaplasia (IM) in the tubular esophagus after 3 or more radiofrequency ablations (RFA) for dysplastic BE, or <50% eradication of Barrett's Esophagus (BE) after 2 RFA treatments.

Condition or disease	Intervention/treatment	Phase
Barrett Esophagus; Intestinal Metaplasia; Esophageal Dysplasia	Device: CryoBalloon Focal Ablation System	Not Applicable

Detailed Description:

Eligibility will be determined based on historical local pathology and medical record information. Informed consent will be obtained and eligible subjects will be treated with the Cryoballoon Focal Ablation System (CbFAS) at baseline.

Subjects will return every 3 months +/- 6 weeks for repeat treatment for up to 12 months OR until complete eradication of intestinal metaplasia (CEIM) and complete eradication of dysplasia (CED) are achieved (at which point subjects enter the follow-up phase), whichever occurs first.

Treatment procedures will be performed on an outpatient basis according to the site's standards of care for anesthesia and sedation during esophagogastroduodenoscopy (EGD) procedures. EGD examinations will be performed using high definition White Light Endoscopy (WLE), plus Narrow Band Imaging (NBI) or i-SCAN to assess BE Prague Score and identify tissue landmarks and ablation zones.

A high definition endoscope will be used for all ablations performed with the CryoBalloon Focal Ablation System (CbFAS). The System will be used according to the instructions for use provided with the product and in accordance with the current standard of care for treatment of BE.

Repeat cryoablation may be performed if esophageal columnar mucosa is visible on EGD or if intervening biopsies (if a site chooses to obtain intervening biopsies as standard of care) are positive for any esophageal columnar epithelium until complete eradication of all unwanted tissue is achieved.

Intervening endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) after enrollment may be performed for nodular areas detected after baseline. EMR/ESD may be performed at the same session as the cryoablation if the EMR/ESD site is >=3cm away from the ablation target site. Cryoablation should be performed before EMR/ESD. If the EMR/ESD site is within 3cm of target treatment area, then CbFAS will be delayed for at least 6 weeks.

Residual islands of columnar mucosa of <5 mm in diameter each and <= 3 total can be treated with Argon Plasma Coagulation (APC) and/or CbFAS at the discretion of the treating physician to avoid over treatment of neo-squamous mucosa.

Stenosis requiring treatment based on the physician's discretion, which develops after enrollment, will be treated with standard of care balloon- or wire-guided dilation. Cryoablation may be performed at the same session if the dilated site is >= 3 cm from the target cryoablation site. Otherwise, cryoablation will be postponed to another visit within 1 month +/- 2 weeks.

When CbFAS treatment is received, subjects will be asked to complete assessments immediately after CbFAS treatment, and will be contacted 1 day, 7 days, and 30 days after the procedure.

If no visible BE is present during the endoscopy, then biopsies will be taken following the standard Seattle biopsy protocol (4 quadrant biopsies at 1cm intervals starting at the gastric cardia 1cm distal to the gastroesophageal junction (GEJ) (top of the gastric folds) and continuing proximally throughout the length of the original extent of BE, including any neosquamous or re-epithelialized tissue).

Biopsies will be read by local expert pathologist. If biopsies indicate CEIM and CED, then subjects will enter the 12 month follow-up phase. If biopsies do not indicate CEIM and CED, then subjects will return for additional CbFAS treatment in 3 months +/-6 weeks.

Non-responders are defined as subjects who have not achieved CEIM and CED at 12 months post baseline CbFAS treatment. Non-responders at 12 months will exit the study and continue treatment at the physician's discretion and according to standard of care at each site.

Subjects who achieve CEIM and CED within 12 months of the baseline CbFAS procedure will enter a 12 month follow-up phase. Subjects will be followed per routine care guidelines for their condition, described below:

Subjects with baseline LGD will return at 6 and 12 months from the initial CEIM and CED date for follow-up (+/-2 weeks). Subjects with baseline HGD or IMC will return at 3, 6, 9, and 12 months from initial CEIM and CED date for follow-up (+/- 2 weeks).

During follow-up procedures, high definition WLE, plus NBI or i-SCAN will be used to assess Prague score, and biopsies will be taken following the standard Seattle biopsy protocol (4 quadrant biopsies at 1cm intervals starting at the gastric cardia 1cm distal to the gastroesophageal junction (GEJ) (top of the gastric folds) and continuing proximally throughout the length of the original extent of BE, including any neosquamous or re-epithelialized tissue). Biopsies will be read by local expert pathologist.

If recurrent BE is detected during follow-up endoscopy with biopsy demonstrating compatible histology, then subjects will be exited from the study and treated at the physician's discretion.

Study participation is complete if: 1) Subject has not reached CEIM and CED at 12 month post baseline treatment; or 2) If BE or dysplasia recur after initial CEIM and CED post enrollment; or 3) After completion of the 12 month follow-up EGD with biopsies.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 70 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)
• Actual Study Start Date: September 4, 2018
• Estimated Primary Completion Date: December 2024
• Estimated Study Completion Date: December 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cryoballoon Focal Ablation System (CbFAS) Treatment; Subjects undergoing CbFAS treatment as part of their clinical care for their condition.	Device: CryoBalloon Focal Ablation System; CryoBalloon Focal Ablation System

Outcome Measures

Primary Outcome Measures :

1. Percentage of all treated Subjects with complete eradication of all intestinal metaplasia (CEIM) within 12 months of enrollment. [ Time Frame: 12 months ]
2. Percentage of all treated subjects with complete eradication of dysplasia (CED) within 12 months of enrollment [ Time Frame: 12 months ]
   Stratified by prior type of ablation treatment and baseline grade (LGD or HGD) will also be reported.
3. Incidence of CryoBalloon-related serious adverse events [ Time Frame: 12 months ]
   Relation of serious adverse events to CryoBalloon device will be assessed by the PI

Secondary Outcome Measures :

1. Technical success rate [ Time Frame: At end of treatment period, up to 12 months ]
   The device worked as expected on every application, defined as proportion of all CbFAS that perform as intended.
2. Procedure success rate [ Time Frame: At end of treatment period, up to 12 months ]
   All columnar tissue that was planned to be treated was treated.
3. Progression rate [ Time Frame: At end of treatment period, up to 12 months ]
   Percentage of subjects with progression of dysplasia from LGD to HGD or esophageal cancer, or progression of HGD to cancer at 12 months from enrollment date.
4. Survival curve analysis - time to CEIM [ Time Frame: At end of treatment period, up to 12 months ]
   Time to complete eradication of intestinal metaplasia (CEIM). Survival curve analysis from first treatment.
5. Survival curve analysis - time to progression [ Time Frame: At end of treatment period, up to 12 months ]
   Time to progression of dysplasia from LGD to HGD or esophageal cancer, or progression of HGD to cancer at 12 months from enrollment date. Survival curve analysis from first treatment.
6. Survival curve analysis - time to recurrence [ Time Frame: At end of treatment period, up to 12 months ]
   Time to recurrence. Survival curve analysis from first treatment.
7. Risk factors associated with failure to respond to CryoBalloon ablation [ Time Frame: At end of treatment period, up to 12 months ]
   Risk factors associated with failure to respond to CryoBalloon ablation
8. Median number of CryoBalloon ablation treatments required to achieve CED and CEIM by 12 months from enrollment date. [ Time Frame: At end of treatment period, up to 12 months ]
   Median number of CryoBalloon ablation treatments required to achieve CED and CEIM by 12 months from enrollment date.
9. Mean number of CryoBalloon ablation treatments required to achieve CED and CEIM by 12 months from enrollment date. [ Time Frame: At end of treatment period, up to 12 months ]
   Mean number of CryoBalloon ablation treatments required to achieve CED and CEIM by 12 months from enrollment date.
10. Proportion of subjects requiring narcotic analgesic - Day 1 [ Time Frame: Day 1 ]
    Proportion of subjects requiring narcotic analgesic at day 1 post treatment.
11. Proportion of subjects requiring narcotic analgesic - Day 7 [ Time Frame: Day 7 ]
    Proportion of subjects requiring narcotic analgesic at day 7 post treatment.
12. Proportion of subjects requiring narcotic analgesic - Day 30 [ Time Frame: Day 30 ]
    Proportion of subjects requiring narcotic analgesic at day 30 post treatment.
13. Median pain score - Day 1 [ Time Frame: Day 1 ]
    Median pain score immediately post-procedure day 1 as assessed by self-reported pain scale (0-10) where 0 is no pain and 10 is worst pain imaginable. Higher scores indicate more severe pain.
14. Median pain score - Day 7 [ Time Frame: Day 7 ]
    Median pain score 7 days after treatment as assessed by self-reported pain scale (0-10) where 0 is no pain and 10 is worst pain imaginable. Higher scores indicate more severe pain.
15. Median pain score - Day 30 [ Time Frame: Day 30 ]
    Median pain score 30 days after treatment as assessed by self-reported pain scale (0-10) where 0 is no pain and 10 is worst pain imaginable. Higher scores indicate more severe pain.
16. Mean pain score - Day 1 [ Time Frame: Day 1 ]
    Mean pain score immediately post-procedure day 1 as assessed by self-reported pain scale (0-10) where 0 is no pain and 10 is worst pain imaginable. Higher scores indicate more severe pain.
17. Mean pain score - Day 7 [ Time Frame: Day 7 ]
    Mean pain score 7 days after treatment as assessed by self-reported pain scale (0-10) where 0 is no pain and 10 is worst pain imaginable. Higher scores indicate more severe pain.
18. Mean pain score - Day 30 [ Time Frame: Day 30 ]
    Mean pain score 30 days after treatment as assessed by self-reported pain scale (0-10) where 0 is no pain and 10 is worst pain imaginable. Higher scores indicate more severe pain.
19. Proportion of Barrett's Esophagus surface area reverted to neosquamous epithelium [ Time Frame: At end of treatment period, up to 12 months ]
    For those who do not achieve CEIM and CED at 12 months from enrollment date, proportion of Barrett's Esophagus surface area reverted to neosquamous epithelium based on physician report.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. History of BE with LGD or HGD confirmed with biopsy, or resected intramucosal cancer (IMC) with low risk of recurrence defined as EMR/ESD pathology results negative for: positive margin, >T1a stage, poorly differentiated carcinoma, and lymphovascular invasion.

2. Prior treatment with RFA who meet either of the following criteria at the enrolling EGD:

   2.1. History of at least 3 RFA treatments, with one or more of the following:

   • 2.1.1. Residual BE Prague >=C1
   • 2.1.2. Residual BE >=M1
   • 2.1.3. One or more islands of residual BE >=1 cm in diameter
   • 2.1.4. Any residual dysplasia in tubular esophagus 2.2. History of at least 2 RFA treatments and < 50% eradication of BE, as judged by estimation of the treating physician.
3. 18 or older years of age at time of consent.
4. Provides written informed consent.
5. Willing to undergo an alternative approved standard of care treatment for their condition.
6. Willing and able to comply with study requirements for follow-up.
7. No prior history of balloon or spray cryotherapy esophageal treatment. Prior APC is allowable.

Exclusion Criteria:

1. Residual BE Prague length measuring >C3 or >M8 after RFA treatment.
2. Dysplasia or IM confined only to the gastric cardia (BE Prague C0M0).
3. Pre-existing esophageal stenosis/stricture preventing advancement of a therapeutic endoscope during screening/baseline EGD. Subjects are eligible if the stenosis/stricture is dilated to at least 15mm, but baseline treatment may need to be delayed per protocol.
4. Symptomatic, untreated esophageal strictures.

5. Any endoscopically-visualized abnormalities such as ulcers, masses or nodules during screening/baseline EGD. Subjects with nodular dysplasia or IMC identified during screening/baseline EGD may be treated with EMR or ESD and return for baseline treatment in this study at least 6 weeks later given that:

   5.1. Follow-up endoscopy must be negative for nodular dysplasia (visually clear of nodular dysplasia).

   5.2. Patients with IMC must be at low risk for recurrence, confirmed by EMR/ESD pathology results negative for: positive margin, >T1a stage, poorly differentiated carcinoma, and lymphovascular invasion.

6. EMR or ESD < 6 weeks prior to baseline treatment.
7. Untreated invasive esophageal malignancy, including margin-positive EMR/ESD.
8. Active reflux esophagitis grade B or higher assessed during screening/baseline EGD.
9. Severe medical comorbidities precluding endoscopy or limiting life expectancy to less than 2 years in the judgment of the endoscopist.
10. Uncontrolled coagulopathy.
11. Inability to hold use of anti-coagulation medications or non-aspirin anti-platelet agents (APAs) for the duration recommended per ASGE guidelines for a high-risk endoscopy procedure.
12. Active fungal esophagitis.
13. Known portal hypertension, visible esophageal varices, or history of esophageal varices.
14. General poor health, multiple co-morbidities placing the patient at risk, or otherwise unsuitable for trial participation.
15. Pregnant or planning to become pregnant during period of study participation.
16. Patient refuses or is unable to provide written informed consent.
17. Prior esophageal surgery with the exception of uncomplicated nissen fundoplication.

Contacts and Locations

Contacts

Contact: Lindsay Cortright, MA; 919-445-4911; lindsay_cortright@med.unc.edu

Contact: Susan Moist, MPH; 919-918-5900; susan_moist@med.unc.edu

Locations

United States, Alabama

University of Alabama at Birmingham; Recruiting

Birmingham, Alabama, United States, 35294

Contact: Alesha Matthews aleshamatthews@uabmc.edu

Principal Investigator: Shajan Peter, MD

United States, District of Columbia

Georgetown University; Recruiting

Washington, District of Columbia, United States, 20057

Contact: Ivy Tesfai Ivysara.N.Tesfai@medstar.net

Contact: Theo Umeh tumeh98@gwu.edu

Principal Investigator: Shervin Shafa, MD

United States, Maryland

Johns Hopkins University; Recruiting

Baltimore, Maryland, United States, 21205

Contact: Hilary Cosby hcosby1@jhmi.edu

Principal Investigator: Marcia Canto, MD

United States, Minnesota

Mayo Clinic Rochester; Recruiting

Rochester, Minnesota, United States, 55905

Contact: Ramona Lansing, RN Lansing.Ramona@mayo.edu

Contact: Melissa Passe passe.melissa@mayo.edu

Principal Investigator: Prasad Iyer, MD

United States, New York

Northwell Health; Recruiting

Lake Success, New York, United States, 11042

Contact: Molly Stewart mstewart8@northwell.edu

Contact: Hye Jeong hjang3@northwell.edu

Principal Investigator: Arvind Trindade, MD

Sub-Investigator: Anil Vegesna, MD

Icahn School of Medicine at Mount Sinai; Not yet recruiting

New York, New York, United States, 10029

Contact: Michel Cohen michele.cohen@mssm.edu

Principal Investigator: Michael Smith, MD

Columbia University; Recruiting

New York, New York, United States, 10032

Contact: Katharine Boyce kb3217@cumc.columbia.edu

Contact: Rowena Fang rf2808@cumc.columbia.edu

Principal Investigator: Julian Abrams, MD

United States, North Carolina

UNC Chapel Hill; Recruiting

Chapel Hill, North Carolina, United States, 27599

Contact: Julia Kim 919-843-3946 julia_kim@med.unc.edu

Contact: Megan Ramsey 919-843-4382 megan_ramsey@med.unc.edu

Principal Investigator: Nicholas J Shaheen, MD, MPH

United States, Ohio

University Hospitals Cleveland Medical Center; Recruiting

Cleveland, Ohio, United States, 44106

Contact: Wendy Brock Wendy.Brock@UHhospitals.org

Principal Investigator: Amitabh Chak, MD

Sub-Investigator: John Dumot, MD

United States, Pennsylvania

Geisinger Clinic; Recruiting

Danville, Pennsylvania, United States, 17822

Contact: Nikolas Antinnes 570-214-5180 nantinnes@geisinger.edu

Principal Investigator: Harshit Khara, MD

Sub-Investigator: David Diehl, MD

United States, South Carolina

Medical University of South Carolina; Recruiting

Charleston, South Carolina, United States, 29425

Contact: Lauren McGarry 843-792-1820 mcgarryl@musc.edu

Contact: Ashley Warden jonesash@musc.edu

Principal Investigator: Puja Sukwhani Elias

Sub-Investigator: Brenda Hoffman

United States, Texas

UTHealth Science Center/Herman Memorial; Recruiting

Houston, Texas, United States, 77030

Contact: Prithvi Patil prithvi.patil@uth.tmc.edu

Contact: Cecilia Lara cecilia.lara@uth.tmc.edu

Principal Investigator: Nirav Thosani, MD

Sponsors and Collaborators

University of North Carolina, Chapel Hill

PENTAX of America, Inc.

Johns Hopkins University

Investigators

• Principal Investigator: Nicholas J Shaheeen, MD, MPH; UNC Chapel Hill

More Information

• Responsible Party: University of North Carolina, Chapel Hill
• ClinicalTrials.gov Identifier: NCT03554356
• Other Study ID Numbers: 18-0388
• First Posted: June 13, 2018
• Last Update Posted: April 11, 2023
• Last Verified: April 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes

Additional relevant MeSH terms:

Barrett Esophagus; Metaplasia; Precancerous Conditions; Neoplasms; Esophageal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Pathologic Processes